Scarica l'app Stockscreener
7.62
2.83%
0.21
Precedente Chiudi:
$7.41
Aprire:
$7.36
Volume 24 ore:
8.48M
Relative Volume:
9.22
Capitalizzazione di mercato:
$377.53M
Reddito:
$89.04M
Utile/perdita netta:
$-241.08M
Rapporto P/E:
-1.2057
EPS:
-6.32
Flusso di cassa netto:
$-194.72M
1 W Prestazione:
-7.97%
1M Prestazione:
-20.87%
6M Prestazione:
-35.86%
1 anno Prestazione:
-58.36%
Intervallo 1D:
$7.21
$7.75
Intervallo di 1 settimana:
$7.21
$8.75
Portata 52W:
$7.21
$28.80
Regenxbio Inc Stock (RGNX) Company Profile
Nome
Regenxbio Inc
Settore
Industria
Telefono
240-552-8181
Indirizzo
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Confronta RGNX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
7.62 | 377.53M | 89.04M | -241.08M | -194.72M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-15 | Ripresa | Morgan Stanley | Overweight |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-06-07 | Iniziato | Goldman | Buy |
| 2024-03-11 | Iniziato | H.C. Wainwright | Buy |
| 2024-03-08 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-03-06 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-02-21 | Ripresa | Raymond James | Outperform |
| 2023-11-01 | Iniziato | Stifel | Buy |
| 2023-06-02 | Iniziato | Robert W. Baird | Outperform |
| 2022-06-23 | Iniziato | Berenberg | Buy |
| 2021-12-15 | Iniziato | Wedbush | Neutral |
| 2021-10-19 | Ripresa | Morgan Stanley | Overweight |
| 2021-01-06 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2020-12-16 | Iniziato | UBS | Buy |
| 2020-06-25 | Ripresa | BofA/Merrill | Buy |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-08-20 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2019-06-18 | Reiterato | Chardan Capital Markets | Buy |
| 2019-06-14 | Ripresa | Raymond James | Outperform |
| 2019-06-05 | Reiterato | Chardan Capital Markets | Buy |
| 2019-02-25 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-02-05 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2018-12-17 | Reiterato | Chardan Capital Markets | Buy |
| 2018-11-08 | Reiterato | BofA/Merrill | Neutral |
| 2018-08-08 | Reiterato | Chardan Capital Markets | Buy |
| 2018-07-23 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-07-10 | Reiterato | Chardan Capital Markets | Buy |
| 2018-05-09 | Reiterato | Barclays | Overweight |
| 2018-04-09 | Reiterato | Chardan Capital Markets | Buy |
| 2018-03-12 | Downgrade | Evercore ISI | Outperform → In-line |
| 2018-02-13 | Iniziato | Mizuho | Neutral |
| 2017-11-09 | Ripresa | Morgan Stanley | Overweight |
Mostra tutto
Regenxbio Inc Borsa (RGNX) Ultime notizie
Stifel Financial Corp Boosts Position in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 4,880 Shares of REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
REGENXBIO to Participate in Upcoming Investor Conferences - Kilgore News Herald
BNP Paribas Financial Markets Purchases 17,533 Shares of REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
Trading (RGNX) With Integrated Risk Controls - Stock Traders Daily
REGENXBIO: A Hidden Gem in Gene Therapy with Promising Pipeline and Growth Potential - mediahousepress
REGENXBIO's SWOT analysis: gene therapy firm's stock poised for growth By Investing.com - Investing.com Australia
REGENXBIO's SWOT analysis: gene therapy firm's stock poised for growth - Investing.com India
National Bank of Canada FI Invests $713,000 in REGENXBIO Inc. (NASDAQ:RGNX) - MarketBeat
Regenxbio stock hits 52-week low at $8.39 amid market challenges - Investing.com Australia
REGENXBIO Inc. (NASDAQ:RGNX) Shares Bought by Charles Schwab Investment Management Inc. - Defense World
Royal Bank of Canada Reiterates “Outperform” Rating for REGENXBIO (NASDAQ:RGNX) - Defense World
REGENXBIO Inc. (NASDAQ:RGNX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
REGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Where Regenxbio Stands With Analysts - Benzinga
Jacobs Levy Equity Management Inc. Trims Position in REGENXBIO Inc. (NASDAQ:RGNX) - MarketBeat
REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2024 Financial Results and Recent Operational Highlights - The Eastern Progress Online
REGENXBIO Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect - The Eastern Progress Online
Regenxbio stock touches 52-week low at $8.51 amid market challenges - Investing.com Canada
(RGNX) Trading Report - Stock Traders Daily
Regenxbio Updates Leadership, Names New CEO - Contract Pharma
REGENXBIO Inc. (NASDAQ:RGNX) is Redmile Group LLC's 10th Largest Position - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Makes New Investment in REGENXBIO Inc. (NASDAQ:RGNX) - MarketBeat
REGENXBIO's SWOT analysis: gene therapy stock poised for growth amid challenges - Investing.com India
How To Trade (RGNX) - Stock Traders Daily
HC Wainwright Cuts REGENXBIO (NASDAQ:RGNX) Price Target to $36.00 - Defense World
REGENXBIO (NASDAQ:RGNX) Given Buy Rating at Chardan Capital - Defense World
Regenxbio price target lowered to $36 from $40 at H.C. Wainwright - MSN
HC Wainwright Has Lowered Expectations for REGENXBIO (NASDAQ:RGNX) Stock Price - MarketBeat
Regenxbio starts pivotal trial testing DMD gene therapy RGX-202 - Muscular Dystrophy News
Leerink Partnrs Increases Earnings Estimates for REGENXBIO - MarketBeat
H.C. Wainwright sees 45% approval probability for RGX-202, reiterates Buy on Regenxbio stock - Investing.com Nigeria
H.C. Wainwright sees 45% approval probability for RGX-202, reiterates Buy on Regenxbio stock By Investing.com - Investing.com South Africa
Chardan Capital Reaffirms Buy Rating for REGENXBIO (NASDAQ:RGNX) - MarketBeat
Regenxbio down 13% ahead of data readout for muscular dystrophy asset - MSN
Regenxbio surges 10% as it launches pivotal phase of muscular dystrophy asset trial - MSN
Regenxbio eyes 2026 filing for Duchenne muscular dystrophy gene therapy - Pharmaceutical Technology
US Bancorp DE Has $26,000 Stake in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
Morgan Stanley Reiterates “Overweight” Rating for REGENXBIO (NASDAQ:RGNX) - Defense World
Raymond James maintains $18 target on RGNX after trial data - Investing.com
Regenxbio Sets Sights On 2026 Filing For DMD Gene Therapy - Citeline
FDA endorses speedy approval path for Regenxbio Duchenne gene therapy - BioPharma Dive
Raymond James maintains $18 target on RGNX after trial data By Investing.com - Investing.com UK
REGENXBIO (NASDAQ:RGNX) Sees Strong Trading VolumeTime to Buy? - MarketBeat
What's Going On With REGENXBIO Shares Monday? - Benzinga
Regenxbio Share Surge 20% on Duchenne Muscular Dystrophy Treatment Trial Data, Expansion - MarketWatch
Regenxbio (RGNX) Initiates Pivotal Phase Of Affinity Duchenne® Trial Of Rgx-202 Gene Therapy And Reports Positive Functional Data - StreetInsider.com
REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA - PR Newswire
Regenxbio Inc Azioni (RGNX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Regenxbio Inc Azioni (RGNX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| KARABELAS ARGERIS N | Director |
Oct 01 '24 |
Sale |
10.11 |
10,000 |
101,052 |
11,286 |
| KARABELAS ARGERIS N | Director |
Sep 03 '24 |
Option Exercise |
3.76 |
10,000 |
37,600 |
21,286 |
| KARABELAS ARGERIS N | Director |
Sep 03 '24 |
Sale |
11.56 |
10,000 |
115,588 |
11,286 |
| Mills Kenneth T. | Director |
Aug 08 '24 |
Option Exercise |
0.85 |
36,316 |
30,869 |
444,351 |
| KARABELAS ARGERIS N | Director |
Aug 01 '24 |
Option Exercise |
3.85 |
10,100 |
38,874 |
21,386 |
| KARABELAS ARGERIS N | Director |
Aug 01 '24 |
Sale |
13.51 |
10,100 |
136,454 |
11,286 |
| Simpson Curran | Chief Executive Officer |
Aug 01 '24 |
Sale |
15.00 |
100 |
1,500 |
170,037 |
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):